Rafael Holdings Narrows Q3 Loss to $1.5M Amidst Zero Revenue
Ticker: RFL · Form: 10-Q · Filed: Jun 11, 2025 · CIK: 1713863
Sentiment: bearish
Topics: Biotech, Holding Company, Net Loss, Zero Revenue, Cash Burn, Speculative Investment, SEC Filing
TL;DR
**RFL is a cash-burning shell with no revenue; avoid unless you're betting on a miracle acquisition.**
AI Summary
Rafael Holdings, Inc. reported no revenue for the three and nine months ended April 30, 2025, consistent with its prior-year periods, as it continues to operate as a holding company with no active business operations. The company posted a net loss of $1.5 million for the three months ended April 30, 2025, a significant improvement from the $10.1 million net loss in the same period last year. For the nine months ended April 30, 2025, the net loss was $4.7 million, down from $28.9 million in the prior year. This reduction in net loss is primarily due to decreased operating expenses following the sale of its oncology assets to Cornerstone Pharmaceuticals, Inc. in 2022. Rafael Holdings maintains a cash balance of $1.9 million as of April 30, 2025, down from $3.4 million at July 31, 2024. The company's strategic outlook remains focused on managing its remaining assets and liabilities, including its investment in Cornerstone Pharmaceuticals, Inc., and exploring potential new business opportunities, though no specific plans are detailed.
Why It Matters
For investors, Rafael Holdings' continued lack of revenue and reliance on managing existing assets signals a highly speculative investment. The significant reduction in net loss from $10.1 million to $1.5 million quarter-over-quarter, while positive, is largely due to the absence of prior operating expenses rather than new business generation. Employees face uncertainty given the company's 'holding company' status and lack of active operations. Customers are not directly impacted as the company has no products or services. In the broader market, RFL's situation highlights the challenges for former biotech companies transitioning to holding entities, especially in a competitive landscape where active innovation is key.
Risk Assessment
Risk Level: high — The risk level is high because Rafael Holdings, Inc. reported zero revenue for the three and nine months ended April 30, 2025, and a net loss of $1.5 million for the quarter. The company's cash balance decreased from $3.4 million at July 31, 2024, to $1.9 million at April 30, 2025, indicating a dwindling cash runway without active operations or new funding sources.
Analyst Insight
Investors should exercise extreme caution and consider divesting from RFL given its lack of revenue, ongoing net losses, and declining cash reserves. This company is highly speculative and suitable only for investors with a very high-risk tolerance looking for potential, but undefined, future strategic shifts.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $0
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$1.5 million
- eps
- N/A
- gross Margin
- N/A
- cash Position
- $1.9 million
- revenue Growth
- N/A
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Total Revenue | $0 | N/A |
Key Numbers
- $0 — Revenue (for the three and nine months ended April 30, 2025, indicating no active business operations)
- $1.5 million — Net Loss (for the three months ended April 30, 2025, an improvement from $10.1 million in the prior year)
- $4.7 million — Net Loss (for the nine months ended April 30, 2025, down from $28.9 million in the prior year)
- $1.9 million — Cash Balance (as of April 30, 2025, a decrease from $3.4 million at July 31, 2024)
- 787,163 shares — Class A common stock outstanding (as of June 9, 2025)
- 34,303,240 shares — Class B common stock outstanding (as of June 9, 2025)
Key Players & Entities
- Rafael Holdings, Inc. (company) — registrant of the 10-Q filing
- Cornerstone Pharmaceuticals, Inc. (company) — recipient of Rafael Holdings' oncology assets in 2022
- New York Stock Exchange (regulator) — exchange where Class B common stock is traded
- NYSE American (regulator) — exchange where warrants to purchase Class B common stock are traded
- SEC (regulator) — regulator for 10-Q filings
FAQ
What were Rafael Holdings' revenues for the quarter ended April 30, 2025?
Rafael Holdings, Inc. reported no revenue for the three months ended April 30, 2025, consistent with the prior-year period, as it operates as a holding company.
How much was Rafael Holdings' net loss for the three months ended April 30, 2025?
Rafael Holdings, Inc. reported a net loss of $1.5 million for the three months ended April 30, 2025, a significant improvement from the $10.1 million net loss in the same period last year.
What is Rafael Holdings' current cash position as of April 30, 2025?
As of April 30, 2025, Rafael Holdings, Inc. had a cash balance of $1.9 million, down from $3.4 million at July 31, 2024.
Why did Rafael Holdings' net loss decrease significantly?
The significant decrease in Rafael Holdings' net loss is primarily due to reduced operating expenses following the sale of its oncology assets to Cornerstone Pharmaceuticals, Inc. in 2022.
What is the primary business of Rafael Holdings, Inc. currently?
Rafael Holdings, Inc. currently operates as a holding company with no active business operations, focusing on managing its remaining assets and liabilities.
What are the risks associated with investing in Rafael Holdings (RFL)?
Investing in Rafael Holdings (RFL) carries high risk due to its zero revenue, ongoing net losses, and declining cash reserves, indicating a lack of sustainable operations.
Where are Rafael Holdings' Class B common stock and warrants traded?
Rafael Holdings' Class B common stock (RFL) is traded on the New York Stock Exchange, and its warrants (RFL-W) are traded on NYSE American.
Has Rafael Holdings filed all required SEC reports?
Yes, Rafael Holdings, Inc. has indicated that it has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
What is Rafael Holdings' strategy for future growth?
Rafael Holdings' strategic outlook involves managing its remaining assets and liabilities, including its investment in Cornerstone Pharmaceuticals, Inc., and exploring potential new business opportunities, though no specific growth plans are detailed.
How many shares of Class B common stock does Rafael Holdings have outstanding?
As of June 9, 2025, Rafael Holdings, Inc. had 34,303,240 shares of Class B common stock outstanding.
Risk Factors
- Limited Cash Reserves [medium — financial]: As of April 30, 2025, the company's cash balance was $1.9 million, a decrease from $3.4 million at July 31, 2024. This reduction in liquidity could impact the company's ability to fund operations or pursue new opportunities.
- Lack of Active Business Operations [high — operational]: Rafael Holdings continues to operate as a holding company with no active business operations, reporting zero revenue for the three and nine months ended April 30, 2025. This lack of operational revenue generation poses a significant risk to future viability.
- Dependence on Investment Value [medium — financial]: The company's strategic outlook includes managing its investment in Cornerstone Pharmaceuticals, Inc. The value and performance of this investment are critical to the company's financial health, and any adverse developments could have a material impact.
- Net Loss Reduction Drivers [medium — financial]: While net losses have significantly decreased from $10.1 million to $1.5 million (quarterly) and $28.9 million to $4.7 million (year-to-date), this is primarily due to reduced operating expenses post-asset sale, not revenue generation. Sustainability of this loss reduction without revenue is a concern.
Industry Context
Rafael Holdings operates within the pharmaceutical preparations sector (SIC 2834). However, as a holding company with no active operations, it is not directly participating in the competitive landscape or industry trends of drug development or manufacturing. Its current focus is on managing its investment portfolio and exploring future opportunities.
Regulatory Implications
As a company with no active business operations, Rafael Holdings faces minimal direct regulatory scrutiny related to product development or sales. However, it must comply with all SEC reporting requirements for publicly traded companies, including timely filing of 10-Q and 10-K reports.
What Investors Should Do
- Monitor the performance and valuation of the investment in Cornerstone Pharmaceuticals, Inc., as it is a key asset for Rafael Holdings.
- Evaluate the company's strategy for exploring new business opportunities and assess the feasibility and potential impact of any future ventures.
- Consider the implications of the declining cash balance ($1.9 million) on the company's ability to sustain operations or invest in new initiatives.
- Analyze the significant disparity in Class A and Class B common stock outstanding, as it may affect corporate governance and future capital raises.
Key Dates
- 2025-04-30: Quarterly period end — Reporting period for the 10-Q, showing zero revenue and a net loss of $1.5 million for the quarter.
- 2025-06-09: Shares outstanding reported — Provides current share counts for Class A (787,163) and Class B (34,303,240) common stock, relevant for per-share calculations and market capitalization.
- 2022-01-01: Sale of oncology assets to Cornerstone Pharmaceuticals, Inc. — This event significantly reduced operating expenses, leading to the improved net loss figures reported in the current period, but also removed the company's primary business operations.
Glossary
- Holding Company
- A company that owns or controls other companies but does not produce goods or services itself. (Explains Rafael Holdings' current operational status and lack of revenue generation.)
- Net Loss
- The total expenses incurred by a company exceed its total revenues over a specific period. (Key metric showing the company's profitability, which has improved but remains negative.)
- Operating Expenses
- Costs incurred by a company in its normal course of business, excluding cost of goods sold. (A significant reduction in these expenses is the primary driver for the improved net loss figures.)
- Class B common stock
- A class of common stock with specific voting rights or other characteristics, distinct from Class A common stock. (The company has a significantly larger number of Class B shares outstanding (34,303,240) compared to Class A (787,163), which could have implications for control and voting power.)
Year-Over-Year Comparison
Compared to prior year periods, Rafael Holdings has seen a dramatic reduction in net losses, with the three-month period ending April 30, 2025, reporting a $1.5 million loss versus $10.1 million in the prior year. This improvement is driven by decreased operating expenses following the sale of its oncology assets, rather than revenue growth, as revenue remains at $0. The cash position has also decreased from $3.4 million at July 31, 2024, to $1.9 million as of April 30, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on June 11, 2025 regarding Rafael Holdings, Inc. (RFL).